ARTICLE | Clinical News
Exisulind: Phase II/III
May 10, 1999 7:00 AM UTC
Columbia University researchers presented interim data from a 96-patient study showing a statistically significant reduction in mean prostate specific antigen (PSA) levels in the exisulind group comp...